Loading data
ORGONasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 564.17 m USD | 482.04 m USD | 433.14 m USD | 450.89 m USD | 467.36 m USD |
| Cost of revenue | — | 115.74 m USD | 106.48 m USD | 105.02 m USD | 114.2 m USD |
| Gross profit | — | 366.3 m USD | 326.66 m USD | 345.87 m USD | 353.16 m USD |
| Research and development expense | 44.54 m USD | 50.27 m USD | 44.38 m USD | 39.76 m USD | 30.74 m USD |
| Selling, general and administrative expense | 326.24 m USD | 294.51 m USD | 269.75 m USD | 283.81 m USD | 250.2 m USD |
| Operating profit | 44.69 m USD | -1.28 m USD | 12.53 m USD | 22.3 m USD | 72.22 m USD |
| Interest expense | — | — | 2.19 m USD | 2.01 m USD | 7.24 m USD |
| Profit before tax | 46.97 m USD | -2.81 m USD | 10.39 m USD | 20.28 m USD | 63.09 m USD |
| Income tax expense | 9.94 m USD | -3.67 m USD | 5.45 m USD | 4.75 m USD | -31.12 m USD |
| Net income (reported basis) | 37 m USD | 900 k USD | 4.9 m USD | 15.5 m USD | 94.2 m USD |
| Net income attributable to common shareholders | 20.02 m USD | -937 k USD | 4.95 m USD | 15.53 m USD | — |
| Basic earnings per share | 0.16 USD/share | -0.01 USD/share | 0.04 USD/share | 0.12 USD/share | 0.73 USD/share |
| Diluted earnings per share | 0.15 USD/share | -0.01 USD/share | 0.04 USD/share | 0.12 USD/share | 0.7 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.